Overview

Pharmacology of Cognition in Schizotypal Personality Disorder

Status:
Terminated
Trial end date:
1997-05-01
Target enrollment:
Participant gender:
Summary
This study will determine the effectiveness of guanfacine in improving cognitive and functional impairments in schizotypal personality disorder.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Guanfacine